ROCR Value Based Program Act
- Bill Number
- S. 1031
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-03-13: Read twice and referred to the Committee on Finance.
- Last Updated
- 2026-04-29T11:03:31Z
AI-Generated Summary
Purpose of the Legislation
The Radiation Oncology Case Rate Value Based Program Act of 2025 (S. 1031) aims to improve Medicare payments for radiation therapy services used to treat cancer and other diseases. It establishes a new value-based payment system that rewards efficient, high-quality care while addressing issues like inconsistent pricing, access barriers (especially in rural areas), and high costs. The bill also creates an exception allowing free or discounted transportation for patients receiving radiation therapy, without violating anti-kickback laws. Overall, it seeks to stabilize payments, enhance patient-centered care, and achieve Medicare savings without reducing access to services.
Key Provisions
- Establishment of the ROCR Program:
- Creates a mandatory Radiation Oncology Case Rate Value Based Payment Program (ROCR Program) under Medicare Part B, starting no later than one year after enactment.
- Provides per-episode payments (a single bundled amount for an entire course of treatment) for radiation therapy services for specific cancer types (e.g., breast, prostate, lung, bone/brain metastases).
- Payments cover professional services (e.g., physician planning) and technical services (e.g., equipment and staffing), split into two halves: the first issued 30 days after treatment starts, the second at the end of the episode (90 days for most cancers, 30 days for bone/brain metastases) or upon patient death.
- Episode of care begins with treatment planning and ends after a set period; incomplete episodes revert to standard fee-for-service payments.
- Base rates derived from 2021 Medicare data, updated annually for inflation, with geographic adjustments for local costs and a "savings adjustment" to reduce overall spending.
- Excludes certain advanced therapies (e.g., proton beam, brachytherapy) for the first 12 years, with potential later inclusion based on stakeholder input.
- Incentives and Adjustments:
- Health Equity Add-On: Up to $500+ per episode (increasing $10 yearly) for providers reporting patient transportation insecurity (via a specific diagnosis code), to fund free/discounted rides (e.g., car services, public transit) within 75 miles or in rural areas. Requires documentation and no marketing of the service.
- Quality Incentives: Initial 1% payment increase for accredited providers (using electronic health records and standards from organizations like the American College of Radiology); after two years, 2.5% reduction for non-accredited providers (exempting "limited resource" ones in underserved areas, capped at 10% of total providers).
- Payment Plans for Coinsurance: Patients pay 20% coinsurance in installments; providers cannot use this as a marketing tool.
- New Technologies: Separate payments during a 12-year transition; special coding and payments for adaptive planning (adjusting treatment mid-course).
- Participation and Exemptions:
- Mandatory for most Medicare-participating radiation therapy providers (hospitals) and suppliers (physician practices or freestanding centers), but optional alongside state innovation models.
- Case-by-case hardship exemptions (e.g., natural disasters).
- Excludes participants from the Merit-based Incentive Payment System (MIPS).
- Transportation Exception:
- Amends anti-kickback laws to allow eligible entities (non-primary healthcare providers) to offer free/discounted non-luxury transportation to established radiation therapy patients, if uniformly applied, not marketed, and costs not shifted to Medicare or patients.
- Reporting and Oversight:
- Government Accountability Office (GAO) reports: One in 3 years on rural access and "radiation therapy deserts" (areas with insufficient services relative to need); another in 7 years evaluating program impacts, access, and potential expansions (e.g., to Medicare Advantage).
- Secretary must use notice-and-comment rulemaking for implementation, with at least 60-day comment periods.
Significant Changes to Existing Law
- New Payment Model: Adds Section 1899C to Title XVIII of the Social Security Act, replacing fragmented fee-for-service and outpatient payments with bundled per-episode rates, independent of treatment site (hospital vs. office).
- Budget Neutrality Exemption: Amends outpatient prospective payment system (Section 1833(t)) and physician fee schedule (Section 1848) to exclude ROCR savings from budget neutrality calculations, allowing net Medicare reductions without offsetting cuts elsewhere.
- Anti-Kickback Amendment: Adds a new exception in Section 1128A(i)(6) for radiation therapy transportation, with strict conditions (e.g., no per-patient driver pay, limited to established patients), and defines terms like "eligible entity" and "rural area."
- MIPS Exclusion: Updates Section 1848(q) to exempt ROCR participants from MIPS performance adjustments.
- Maintains pre-implementation payment rates to avoid disruptions.
Potential Impacts
- Government Agencies: Centers for Medicare & Medicaid Services (CMS) will face new rulemaking, rate-setting, and oversight duties (e.g., audits for add-on payments), potentially increasing administrative costs short-term but yielding long-term savings (targeted reductions via bundled payments). GAO reports may inform future policy.
- Citizens: Medicare beneficiaries (especially the ~60% of cancer patients needing radiation therapy) could see improved access in rural/underserved areas, shorter treatments, and help with transportation barriers, reducing out-of-pocket burdens via payment plans. However, mandatory participation might limit provider choices if exemptions are rare.
- International Relations: No direct impacts; this is a domestic Medicare reform.
Main Stakeholders Affected
- Medicare Beneficiaries: Primarily older adults with included cancers, gaining from equitable access and quality incentives but facing potential provider consolidations.
- Radiation Therapy Providers and Suppliers: Hospitals, physician practices, and freestanding centers must adapt to bundled payments and accreditation, with incentives for equity and quality but risks of payment cuts for non-compliance.
- Healthcare Organizations: Groups like the American Society for Radiation Oncology provide input on standards; technology vendors benefit from new code development for adaptive therapies.
- Federal Government: CMS implements and funds the program; Congress receives evaluations for adjustments.
- Patients and Advocates: Benefit from transportation aid and reports on access deserts, potentially expanding services like proton therapy later.
Notable Legal, Constitutional, or Political Implications
- Legal: Introduces a statutory payment bundle exempt from budget neutrality (a departure from typical Medicare rules), potentially reducing litigation over rate cuts. The anti-kickback exception balances patient access with fraud prevention via strict safeguards (e.g., uniform policies, no cost-shifting). Requires CMS to consult stakeholders, ensuring procedural fairness under the Administrative Procedure Act.
- Constitutional: No direct challenges; aligns with Congress's spending power under Article I for Medicare reforms promoting general welfare through efficient healthcare.
- Political: Bipartisan sponsorship (Sens. Tillis and Peters) highlights consensus on cancer care access amid rising Medicare costs (~$4.2 billion annually for radiation). Could set precedent for value-based models in other specialties, influencing debates on healthcare spending and rural equity, but faces scrutiny over mandatory participation and savings targets.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (4)
Sen. Peters, Gary C. [D-MI], Sen. Marshall, Roger [R-KS], Sen. Coons, Christopher A. [D-DE], Sen. Sullivan, Dan [R-AK]
Recent Actions
- 2025-03-13: Read twice and referred to the Committee on Finance.
- 2025-03-13: Introduced in Senate
Bill Versions
- Radiation Oncology Case Rate Value Based Program Act of 2025 — issued 2025-03-13 — PDF (51 pages)